Search

Upregulation of a cyclin D gene determined by expression microarrays is an almost universal event in MM, but this finding has not been properly confirmed at the protein level. For this reason, we carried out a quantitative analysis of cyclin D proteins using a capillary electrophoresis nanoimmunoassay in newly diagnosed MM patients. Exclusive expression of cyclin D1 and D2 proteins was detected in 54/165 (33%) and 30/165 (18%) of the MM patients, respectively. It is of note that cyclin D1 or D2 proteins were undetectable in 41% of the samples. High levels of cyclin D1 protein were strongly associated with the presence of t(11;14) or 11q gains. However, cyclin D2 protein was detected in all the cases bearing t(14;16), but in only 24% of patients with t(4;14). The presence of cyclin D2 was associated with shorter OS (HR=2.14, p=0.017), although patients overexpressing cyclin D2, but without 1q gains, had a favorable prognosis. In conclusion, although one of the cyclins D is overexpressed at the mRNA level in almost all MM patients, in approximately half of the patients this does not translate into detectable protein. This implies that cyclins D could not play an oncogenic role in a proportion of patients with MM.